Targeted modulation of MGMT: Clinical implications

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 328-331

  Liu, Lili ^a   Gerson, Stanton L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARCINOGEN; CARMUSTINE; GUANINE; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; STREPTOZOCIN; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER RESISTANCE; DNA ADDUCT; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; GENE TARGETING; HUMAN; MAXIMUM TOLERATED DOSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HUMANS; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 31544464704     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2543     Document Type: Review

References (40)

1. 6-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
2. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307.
3. 6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1- nitrosourea. Proc Natl Acad Sci U S A 1985;82:2985-9.
4. 6-Alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance. Hematol Oncol Clin North Am 1995;9:431-50.
5. Lindahl T, Sedgewick B, Sekiguchi M, Nakabeppu Y. Regulation and expression of the adaptive response to alkylatingagents. Annu Rev Biochem 1988;57:133-57.
6. Erickson LC, Laurent G, Sharkey NA, Kohn KW. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumor cells. Nature 1980;288:727-9.
7. Hickman MJ, Samson LD. Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. Mol Cell 2004;14:105-16.
8. 6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986;7:745-9.
9. 6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 1989;70:573-7.
10. 6-methylguanine-DNA methyl-transferase in cell survival, mutagenesis, and carcinogenesis. Mutat Res 1985;145:1-16.
11. 6-methylguanine-DNA methyltransferase promoter: correlation with gene suppression. Carcinogenesis 1995;16:1385-90.
12. 6-methylguanine DNA methyltransferase (mgmt) gene correlates with mgmt expression in human glioma cells. J Biol Chem 1994;269:17228-37.
13. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005;97:1330-8.
14. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71.
15. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
16. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
17. 6- methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors. Proc Natl Acad Sci U S A 1996;93:6941-6.
18. Stupp R, Mason WP, van den Brent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma. N Engl J Med 2005;352:987-96.
19. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
20. 6- benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990;87:5368-72.
21. 6-methylguanine. Biochem Pharmacol 1992;43:1101-7.
22. 6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999;59:2402-10.
23. Clemons M, Kelly J, Watson AJ, et al. O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer 2005;93:1152-6.
24. Woolford LB, Southgate TD, Margison GP, Milsorn MD, Fairbairn LJ. The P140K mutant of human O(6)-methylguanine-DNA- methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine. J Gene Med 2006;8:29-34.
25. Reese JS, et al. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure. J Hematother Stem Cell Res 2001;10:115-23.
26. 6-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 2000;95:3078-84.
27. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1- nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1- nitrosourea-resistant human colon cancer xenografts. Hum Gene Ther 1999;10:1021-30.
28. 6-mehtylguanine-DNA adducts protects transgenic mice from N-methyl-nitrosourea-induced thymic lymphomas. Cancer Res 1994;54:4648-52.
29. + hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol Ther 2002;5:381-7.
30. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl) nitrosourea. Cancer Res 1996;56:5375-9.
31. 5-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl) 1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 2003;304:661-8.
32. 6-benzylguanine-resistant alkyltransferase mutations in mismatch repair-deficient colon cancer. Cancer Res 2002;62:3070-6.
33. 6-alkylguanine-DNA alkyltransferase mutations. Mol Cancer Ther 2004;3:1127-35.
34. 6-methylguanine and the cytotoxicity of methylating agents. Mutat Res 2000;462:71-82.
35. Sobol RW, Horton JK, Kuhn R, et al. Requirement of mammalian DNA polymerase β in base excision repair. Nature 1996;379:183-6.
36. Engelward BP, Dreslin A, Christensen J, Huszar D, Kurahara C, Samson L. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J 1996;15:945-52.
37. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair deficient and proficient colon cancer cells to methylating agents. Clin Cancer Res 1999;5:2908-17.
38. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 2002;8:2985-99.
39. Liu L, Van L, Donze JR, Gerson SL. Blockage of abasic site repair enhances antitumor efficacy of BCNU in colon tumor xenografts. Mol Cancer Ther 2003;2:1061-78.
40. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005;65:6394-400.